Actinium Pharmaceuticals
Cash Flow
Last updated:
Cash flow statement presents a set of outflows and inflows of cash within a company through operating, investing and financing activities. Over the last year, operating activities of Actinium Pharmaceuticals generated cash of -$47,335,000, which is less than the previous year. Cash used in financing activities reached the amount of $14,870,000 last year. Net change in cash is therefore -$32,618,000.
Cash Flow
| 2014 | -14.34M | -186.42K | 15.70M |
|---|---|---|---|
| 2015 | -18.54M | -47.78K | 37.52M |
| 2016 | -20.78M | -109.81K | 15.77M |
| 2017 | -21.55M | -380.94K | 18.81M |
| 2018 | -20.57M | -96.09K | 16.98M |
| 2019 | -21.46M | -63.89K | 17.11M |
| 2020 | -21.61M | -253K | 76.17M |
| 2021 | -20.86M | -133K | 35.22M |
| 2022 | 8.64M | -366K | 23.10M |
| 2023 | -47.33M | -153K | 14.87M |
ATNM Cash Flow Statement (2014 – 2023)
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | |
|---|---|---|---|---|---|---|---|---|---|---|
Cash at beginning of period | 109.60M | 78.22M | 63.99M | 9.69M | 14.10M | 17.79M | 20.51M | 25.64M | 6.70M | 5.53M |
Operating activities | ||||||||||
Net income | -48.81M | -33.01M | -24.77M | -22.21M | -21.89M | -23.65M | -26.60M | -24.32M | -21.02M | -24.68M |
| Adjustments to reconcile net income to cash generated by operating activities: | ||||||||||
Depreciation and amortization | 790K | 699K | 524K | 447K | 420.08K | 50.72K | 55.93K | 77.52K | 53.46K | 37.90K |
Stock-based compensation expense | 3.84M | 2.79M | 1.69M | 1.25M | 1.29M | 0 | 3.49M | 4.29M | 7.06M | 6.28M |
| Deferred income tax benefit | 3.84M | 2.79M | 1.69M | 1.25M | 1.29M | 0 | 3.49M | 4.29M | 7.06M | 6.28M |
| Changes in operating assets and liabilities: | ||||||||||
Accounts receivable, net | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Inventories | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Accounts payable | -2.17M | 4.59M | 1.19M | -257K | -1.25M | 1.13M | 405.21K | 2.72M | -793.94K | 1.87M |
Cash generated by operating activities | -47.33M | 8.64M | -20.86M | -21.61M | -21.46M | -20.57M | -21.55M | -20.78M | -18.54M | -14.34M |
Investing activities | ||||||||||
Purchases Of Investments | 0 | 0 | 0 | 0 | 0 | 0 | -356.20K | -49.85K | 0 | 0 |
Investments In Property Plant And Equipment | -153K | -366K | -133K | -253K | -63.89K | -96.09K | -24.73K | -59.96K | -47.78K | -151.68K |
Acquisitions Net | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Cash generated by investing activities | -153K | -366K | -133K | -253K | -63.89K | -96.09K | -380.94K | -109.81K | -47.78K | -186.42K |
Financing activities | ||||||||||
Common Stock Issued | 14.61M | 23.15M | 35.3M | 76.58M | 15.93M | 16.97M | 18.81M | 16.02M | 37.63M | 0 |
Payments for dividends | 0 | 0 | 0 | 0 | -1.26K | 0 | 0 | 0 | 0 | 0 |
Repurchases of common stock | 0 | 0 | 0 | 1K | 0 | 0 | 0 | 0 | 0 | 0 |
Repayments of term debt | -4K | -49K | -85K | -460K | -322K | 0 | 0 | -265.69K | -283.55K | 0 |
Cash used in financing activities | 14.87M | 23.10M | 35.22M | 76.17M | 17.11M | 16.98M | 18.81M | 15.77M | 37.52M | 15.70M |
Net Change In Cash | -32.61M | 31.38M | 14.22M | 54.30M | -4.41M | -3.68M | -3.11M | -5.12M | 18.93M | 1.17M |
Cash at end of period | 76.99M | 109.60M | 78.22M | 63.99M | 9.69M | 14.10M | 17.39M | 20.51M | 25.64M | 6.70M |
| Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source |